Abstracts

541 – Viro-Immunologic Success Against the Odds: 7-Year Outcome in People With 4-Class Drug-Resistant HIV 

Background Heavily treatment-experienced (HTE) people with HIV (PWH) are at increased risk of suboptimal virological suppression and immune recovery. Our aim was to assess these outcomes longitudinally in individuals with 4-class drug resistance (4DR). Methods Repeated cross-sectional analyses were conducted in the PRESTIGIO Registry, an ongoing multicenter cohort that prospectively collects data and provides multidisciplinary evaluation…

987 – Characterization of HIV Acquisitions on Long-Acting Cabotegravir PrEP From ImPrEP CAB Brasil

Background HIV acquisition during long-acting cabotegravir (CAB) PrEP is rare but poses significant challenges for HIV detection and monitoring within prevention programs. We present the first analysis of HIV-1 acquisitions on CAB PrEP in routine public health settings in Brazil. Methods ImPrEP CAB Brasil is an implementation study of same‐day CAB initiation at oral PrEP…

1006 – Should We Study PrEP Adverse Events in Adolescents? Value of Information and Implementation Analyses

Background Generic tenofovir-disoproxil-fumarate/emtricitabine (TDF-FTC) is cost-effective compared to tenofovir-alafenamide/emtricitabine (TAF-FTC) for HIV pre-exposure prophylaxis (PrEP) among US young men who have sex with men (YMSM). Despite high cost, 37% of providers prescribe TAF-FTC over TDF-FTC for YMSM, in part due to uncertainty around TDF-FTC adverse events (AEs) among adolescents. Methods Using the CEPAC-Adolescent microsimulation model,…

549 – Housing Status and HIV Viral Suppression Across 4 United States Cohorts

Background People with HIV (PWH) in the US experience homelessness at greater proportions than the general population. There remains a lack of understanding regarding HIV clinical care outcomes, including achievement of viral suppression, among PWH experiencing homelessness in different settings. Methods We evaluated associations between housing status and HIV viral suppression using harmonized data from four…

1053 – Medicaid and State AIDS Drug Assistance Programs: The Impact of the Public Health Emergency

Background The Families First Coronavirus Response Act mandated continuous Medicaid coverage during the COVID-19 Public Health Emergency (PHE; March 2020–May 2023), ensuring uninterrupted coverage for millions, including low-income people with HIV (PWH). When the PHE ended, states resumed Medicaid determinations, leading to disenrollments. As the safety net for uninsured PWH, the demand for the AIDS…

1082 – HIV Incidence, Oral, and LAI PrEP Use Among Young Adults With Serious Mental Illness in the US

Background Most (>50%) new HIV diagnoses occur in adolescents and young adults (AYA; 14-35 yrs). Onset of severe mental illnesses (SMI) like schizophrenia and bipolar disorder (BD) coincides with this developmental period and significantly elevates HIV risk. Very little research has examined use of highly-effective pre-exposure prophylaxis (PrEP) for HIV prevention among AYA-SMI. Methods We…

650 – Predictors of Cardiovascular Events Among Ugandan Adults on Long-Term ART: A Prospective Study

Background  People living with HIV (PLWH) face a two-fold increased lifetime risk of cardiovascular (CDV) diseases compared to those without. This trend that has become more evident as ART has extended life expectancy. Nearly two-thirds of PLWH live in Sub-Saharan Africa, where evidence on long-term CDV outcomes remains limited. We conducted a prospective study within…

659 – HIV and Aging Are Associated With CKM Burden Among People Who Inject Drugs

Background Cardiovascular (CVD)–kidney–metabolic (CKM) syndrome integrates overlapping risks of cardiovascular, metabolic, and kidney disease. Its pathophysiology is driven by chronic systemic inflammation and metabolic dysfunction, further amplified in people with HIV (PWH). Among people who inject drugs (PWID), the convergence of HIV and comorbidities may accelerate CKM progression. However, longitudinal CKM trajectories in PWH, particularly…

574 – bNAb Sensitivity Does Not Fully Explain Posttreatment Control in Early HIV-Treated Women During ATI

Background Broadly neutralizing antibodies (bNAbs) VRC07-523LS (VRC07) and CAP256V2LS (CAP256), and vesatolimod were evaluated in a Phase 2a HIV cure study in acutely treated women with HIV-1 in South Africa (NCT05281510).  Four of 20 participants maintained post-treatment control without restarting antiretroviral treatment (ART) during 56 weeks of analytical treatment interruption (ATI). Here we investigated changes in…